MalariaPhase 1/2DSMOZ-2NCT02573857
A Study to Characterise the Antimalarial and Transmission Blocking Activity of a Single Dose of DSM265 or OZ439 in Healthy Subjects With Induced Blood Stage Plasmodium Falciparum or Plasmodium Vivax Infection
A Phase 1/2 study testing DSM265 and OZ439 in people with Malaria, run by Medicines for Malaria Venture at 1 site in Australia.
Trial summary
Part A -Cohort 1 DSM265 will be administered as a single dose (400 mg). For cohort 1 only, an additional single dose (400 mg) of DSM265 may be given if gametocytemia develops. Treatment with DSM265 will be given after an overnight fasting period of ≥ 8 hours. Read more about this study
- Who is it for?
- Ages 18 to 55 yearsHealthy volunteers can take part
- Conditions the study is for
- Malaria
- What is being tested?
- DSM265 and OZ439
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 16 participants
- Where
- 1 siteAustralia
- Study dates
- Oct 2015to May 2016
- Phase
- Phase 1/2
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 55 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Health status:
- Certified as healthy by a comprehensive clinical assessment (detailed medical history and complete physical examination).
- Normal vital signs after 5 minutes resting in supine position:
- 90 mmHg < systolic blood pressure (SBP) <140 mmHg,
- 50 mmHg < diastolic blood pressure (DBP) <90 mmHg,
- 40 bpm< heart rate (HR) <100 bpm.
Show all 26Show fewer
- Normal standard 12-lead electrocardiogram (ECG) after 5 minutes resting in supine position, QTcF≤450 ms (males and females) with absence of second or third degree atrioventricular block or abnormal T wave morphology.
- Laboratory parameters within the normal range, unless the Investigator considers an abnormality to be clinically irrelevant for healthy participants enrolled in this clinical investigation. More specifically for serum creatinine, hepatic transaminase enzymes (aspartate aminotransferase, alanine aminotransferase), and total bilirubin (unless the Participant has documented Gilbert syndrome) should not exceed the upper laboratory norm and haemoglobin must be equal or higher than the lower limit of the normal range
- As there is the risk of adverse effects of the investigational drugs (DSM265 and OZ439), and standard curative treatment (Riamet and primaquine - cohort 1 only) in pregnancy, it is important that any participants involved in this study do not get pregnant or get their female partners pregnant (refer to Section 6.7).
- For cohort 1 and 3 (treatment with DSM265):
- Female participants of childbearing potential (WOCBP) may be enrolled in the DSM265 cohorts but must have adequate contraception in place for the duration of the study and up to 60 days (9 weeks) after the last dose of DSM265, with adequate contraception defined as:
- Stable hormonal contraception (with an approved oral, transdermal or depot regimen) for at least 3 months prior to screening i.e. oral contraceptives, either combined or progestogen alone, hormonal implantable contraception, vaginal ring, contraceptive patches
- Intrauterine (IUD) device or system in place for at least 3 months prior to screening
- Male partner sterilization prior to the female participant's entry into the study, and this male is the sole partner for that participant Abstinent female participants must agree to start a double method if they start a sexual relationship during the study and for up to 60 days (9 weeks) following the last dose of DSM265.
- Male participants to be dosed with DSM265 in cohort 1 or 3 must agree to use a double method of contraception including condom plus diaphragm or condom plus stable oral/transdermal/injectable hormonal contraceptive by female partner from at least 14 days prior to the time of the dose of the study drug through 120 days (17 weeks) after the last dose of DSM265.
- Abstinent male participants must agree to start a double method if they start a sexual relationship during the study and for up to 120 days (17 weeks) weeks following the last dose of DSM265.
- For cohort 2 (treatment with OZ439):
- Female subjects must be considered as women of not childbearing potential (WONCBP) to be eligible. WONCBP is defined as:
- Spontaneous amenorrhoea for at least 1 year or spontaneous amenorrhea for at least 6 months confirmed by an FSH result above the laboratory defined range for post-menopausal
- or permanently sterilised (eg tubal occlusion, hysterectomy, bilateral salpingectomy) Female subjects with same sex partners (abstinence from penile-vaginal intercourse), are eligible when this is their preferred and usual lifestyle.
- Male participants to be dosed with OZ439 in cohort 2 must agree to use a double method of contraception including condom plus diaphragm or condom plus stable oral/transdermal/injectable hormonal contraceptive by female partner from at least 14 days prior to the time of the dose of the study drug through 96 days (14 weeks) after the last dose of OZ439.
- Abstinent male participants must agree to start a double method if they start a sexual relationship during the study and for up to 96 days (14 weeks) following the last dose of OZ439.
- For Part B only (cohort 2 and 3):
- All subjects must be Duffy Blood group positive. Female subjects of childbearing potential (Cohort 3 only) should be blood group Rh positive.
- Regulations:
- Having given written informed consent prior to undertaking any study-related procedure.
Who cannot join
- Medical history and clinical status:
- Any history of malaria or participation to a previous malaria challenge study
- Must not have travelled to or lived in a malaria-endemic country during the past 12 months or planned travel to a malaria-endemic country during the course of the study.
- Has evidence of increased cardiovascular disease risk (defined as >10%, 5 year risk) as determined by the Australian Absolute Cardiovascular Disease Risk Calculator (http://www.cvdcheck.org.au/). Risk factors include sex, age, systolic blood pressure (mm/Hg), smoking status, total and HDL cholesterol (mmol/L), and reported diabetes status.
- History of splenectomy.
- Presence or history of drug hypersensitivity, or allergic disease diagnosed and treated by a physician or history of a severe allergic reaction, anaphylaxis or convulsions following any vaccination or infusion.
Show all 52Show fewer
- Presence of current or suspected serious chronic diseases such as cardiac or autoimmune disease (HIV or other immunodeficiencies), insulin-dependent and non-insulin dependent diabetes, progressive neurological disease, severe malnutrition, acute or progressive hepatic disease, acute or progressive renal disease, psoriasis, rheumatoid arthritis, asthma, epilepsy or obsessive compulsive disorder
- History of malignancy of any organ system (other than localized basal cell carcinoma of the skin or in situ cervical cancer), treated or untreated, within 5 years of screening, regardless of whether there is evidence of local recurrence or metastases
- Participants with history of schizophrenia, bi-polar disease, or other severe (disabling) chronic psychiatric diagnosis including depression or receiving psychiatric drugs or who has been hospitalized within the past 5 years prior to enrollment for psychiatric illness, history of suicide attempt or confinement for danger to self or others.
- Frequent headaches and/or migraine, recurrent nausea, and/or vomiting (more than twice a month)
- Presence of acute infectious disease or fever (e.g., sub-lingual temperature ≥ 38.5°C) within the five days prior to inoculation with malaria parasites.
- Evidence of acute illness within the four weeks before trial prior to screening that the Investigator deems may compromise subject safety.
- Significant inter-current disease of any type, in particular liver, renal, cardiac, pulmonary, neurologic, rheumatologic, or autoimmune disease by history, physical examination, and/or laboratory studies including urinalysis.
- Participant has a clinically significant disease or any condition or disease that might affect drug absorption, distribution or excretion, e.g. gastrectomy, diarrhoea.
- Participation in any investigational product study within the 12 weeks preceding the study.
- Blood donation, any volume, within 1 month before inclusion or participation in any research study involving blood sampling (more than 450 mL/ unit of blood), or blood donation to Red Cross (or other) blood bank during the 8 weeks preceding the reference drug dose in the study.
- Participant unwilling to defer blood donations to the Australian Red Cross Blood Service (ARCBS) for 6 months.
- Medical requirement for intravenous immunoglobulin or blood transfusions.
- Participant who has ever received a blood transfusion.
- Symptomatic postural hypotension at screening, irrespective of the decrease in blood pressure, or asymptomatic postural hypotension defined as a decrease in systolic blood pressure ≥20 mmHg within 2-3 minutes when changing from supine to standing position.
- History or presence of alcohol abuse (alcohol consumption more than 40 g per day) or drug habituation, or any prior intravenous usage of an illicit substance.
- Smoking more than 5 cigarettes or equivalent per day and unable to stop smoking for the duration of the study.
- Ingestion of any poppy seeds within the 24 hours prior to the screening blood test (participants will be advised by phone not to consume any poppy seeds in this time period).
- Excessive consumption of beverages containing xanthine bases, including Red Bull, chocolate etc. more than 400 mg caffeine per day (equivalent to more than 4 cups per day)
- Interfering substance:
- Any medication (including St John's Wort) within 14 days before inclusion or within 5 times the elimination half-life (whichever is longer) of the medication
- Any vaccination within the last 28 days.
- Any corticosteroids, anti-inflammatory drugs, immunomodulators or anticoagulants. Any participant currently receiving or having previously received immunosuppressive therapy, including systemic steroids including adrenocorticotrophic hormone (ACTH) or inhaled steroids in dosages which are associated with hypothalamic-pituitary-adrenal axis suppression such as 1 mg/kg/day of prednisone or its equivalent or chronic use of inhaled high potency corticosteroids (budesonide 800 μg per day or fluticasone 750 μg).
- Any recent (< 6 weeks) or current systemic therapy with an antibiotic or drug with potential anti-malarial activity (i.e. chloroquine, piperaquine, benzodiazepine, flunarizine, fluoxetine, tetracycline, azithromycin, clindamycin, hydroxychloroquine, etc.)
- General conditions:
- Any participant who, in the judgment of the Investigator, is likely to be noncompliant during the study, or is unable to cooperate because of a language or mental deficit.
- Any participant in the exclusion period of a previous study according to applicable regulations.
- Any participant who lives alone (from Day 0 until at least the end of the anti-malarial drug treatment).
- Any participant who cannot be contacted in case of emergency for the duration of the trial and up to 2 weeks following end of study visit.
- Any participant who is the Investigator or any sub-investigator, research assistant, pharmacist, study coordinator, or other staff thereof, directly involved in conducting the study.
- Any participant without a good peripheral venous access.
- Biological status
- Positive result on any of the following tests: hepatitis B surface (HBs Ag) antigen, anti-hepatitis B core antibodies (anti-HBc Ab), anti-hepatitis C virus (anti-HCV) antibodies, anti-hepatitis A or E virus (IgM) antibodies, anti-human immunodeficiency virus 1 and 2 antibodies (anti-HIV1 and anti HIV2 Ab)
- Any drug listed in Table 2 (Drug Screening) in the urine drug screen unless there is an explanation acceptable to the medical investigator (e.g., the participant has stated in advance that they consumed a prescription or OTC product which contained the detected drug) and/or the Participant has a negative urine drug screen on retest by the pathology laboratory.
- Specific to the study
- Cardiac/QT risk
- Family history of sudden death or of congenital prolongation of the QTc interval or known congenital prolongation of the QTc interval or any clinical condition known to prolong the QTc interval.
- History of symptomatic cardiac arrhythmias or with clinically relevant bradycardia. Electrolyte disturbances, particularly hypokalaemia, hypocalcaemia, or hypomagnesaemia.
- Electrocardiogram (ECG) abnormalities in the standard 12-lead ECG (at screening) which in the opinion of the Investigator is clinically relevant or will interfere with the ECG analyses on study
- Known hypersensitivity to DSM265 or OZ439, or any of its excipients or 4-aminoquinolines, artemether or other artemisinin derivatives, lumefantrine, or other arylaminoalcohols.
- Known severe reaction to mosquito bites other than local itching and redness.
- Unwillingness to abstain from consumption of citrus (grapefruit, Seville orange, etc.) for ≥21 days prior to initiation of the study (inoculation; Day 0) and for the study duration.
- Unwillingness to abstain from consumption of quinine containing foods/beverages such as tonic water, lemon bitter, from inoculation (Day 0) to the end of the malaria treatment.
- Any history or presence of lactose intolerance.
- Use of prescription drugs, herbal supplements, within four weeks prior to administration of the study drug, and/or over-the-counter (OTC) medication, dietary supplements (including vitamins) within two weeks prior to initial dosing (Note: diazepam interferes with the analysis of blood levels of DSM265 and thus should not have been used for at least 8 weeks prior to administration of the study drug). If needed (i.e. an incidental and limited need) paracetamol is acceptable up to 4 g/day.
- Participants are requested to refrain from taking non-approved concomitant medication from recruitment until the conclusion of the study.
- Participants who are excluded from participation on study days for any of the above reasons may be eligible to participate on a postponed schedule if the Investigator considers this appropriate.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: A Phase Ib Study to Characterise the Antimalarial and Transmission Blocking Activity of a Single Dose of DSM265 or OZ439 in Healthy Subjects With Induced Blood Stage Plasmodium Falciparum or Plasmodium Vivax Infection
Part A
-Cohort 1 DSM265 will be administered as a single dose (400 mg). For cohort 1 only, an additional single dose (400 mg) of DSM265 may be given if gametocytemia develops. Treatment with DSM265 will be given after an overnight fasting period of ≥ 8 hours. If dosing is to occur in the evening, subjects will be required to fast for ≥4 hours prior to receiving treatment. Subjects will be required to fast for a further four hours anytime after dosing with DSM265.
Read more
Part B
- Cohort 2 OZ439 will be administered as a single 200 mg dose. If recrudescence is observed, a single 400 mg dose of OZ439 will be given. Treatment with OZ439 will be administered after an overnight fasting period of ≥ 6 hours. If dosing is to occur in the evening, subjects will be required to fast for ≥4 hours prior to receiving treatment. Participants will drink 200 mL of milk prior to drug administration, and then swallow the appropriate volume of OZ439 suspension. Subjects will be required to fast for a further six hours anytime after dosing with OZ439.
- Cohort 3 DSM265 will be administered as a single dose (400 mg) as described for cohort 1. No additional dose will be administered.
Read the detailed description
This is a single-centre, open label study using induced blood stage malaria (IBSM) infection to assess the effectiveness of the investigational drugs DSM265 or OZ439 in reducing parasitemia. Transmission blocking activity of DSM265 (in P. falciparum infection; cohort 1 only) and infectivity to vector mosquitoes prior to drug treatment (in P. vivax infection; cohort 2 and 3) will also be assessed. This study will be conducted in up to three cohorts (n = 8 per cohort), and will be divided into 2 parts. In Part A (cohort 1) the efficacy of a single administration of 400 mg DSM265 for the clearance of asexual blood stages of P. falciparum will be determined. Activity of a second single dose of 400 mg DSM265 against gametocytes will be assessed in this cohort only if sexual stages are identified by PCR following the initial drug treatment. In Part B, subjects will be infected with P. vivax by IBSM, then treated with a single 200 mg dose OZ439 (cohort 2) or 400 mg dose of DSM265 (cohort 3). For cohort 2, if recrudescence occurs following initial drug treatment with 200 mg OZ439, then affected participants who reach the treatment threshold will receive a single 400 mg dose of OZ439. The PK/PD relationship following drug treatment will be determined in order to further characterize the antimalarial activity of the investigational drug in the IBSM system using P. falciparum (for cohort 1; 400 mg DSM265) or P. vivax (for cohort 2, 200 mg OZ439; cohort 3, 400 mg DSM265).
The treatment effects on gametocytemia (if sexual blood stages are detected by PCR) and transmission blocking activity of DSM265 will be investigated as a secondary objective for cohort 1 (P. falciparum infection). Prior to drug treatment, the infectivity of P. vivax IBSM infection to vector mosquitoes will also be investigated as a secondary objective for Part B, cohorts 2 and 3. The exposures achieved with the doses proposed for DSM265 used in Part A and DSM265 or OZ439 in Part B are associated with a safety profile which is well described from previous studies and significantly below the maximum tolerated exposures reported for either drug.
- Conditions
- Malaria
- Being tested
- DSM265, OZ439
- Keywords
- Induced blood stage malaria, Transmission, Gametocytemia
- Medical subject headings
- Malaria
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
DSM265Drug
Oral suspension from bulk powder
OZ439Drug
Also called Artefenomel
Oral suspension from powder in a bottle
| Study group | Role | What they receive |
|---|---|---|
| DSM265 P. falciparum | Experimental | Cohort 1: the efficacy of a single administration of 400 mg DSM265 for the clearance of asexual blood stages of P. falciparum will be determined. Activity of a second single dose of 400 mg DSM265 against gametocytes will be assessed in this cohort only if sexual stages are identified by PCR following the initial drug treatment. Receives: Drug: DSM265 |
| OZ439 P. vivax | Experimental | Cohort 2: subjects will be infected with P. vivax by IBSM, then treated with a single 200 mg dose OZ439. If recrudescence occurs following initial drug treatment with 200 mg OZ439, then affected participants who reach the treatment threshold will receive a single 400 mg dose of OZ439. Receives: Drug: OZ439 |
| DSM265 P. vivax | Experimental | Cohort 3: subjects will be infected with P. vivax by IBSM, then treated with a single 400 mg dose of DSM265 Receives: Drug: DSM265 |
What is being measured
The primary outcome is the main question the study is designed to answer.
Efficacy (PRR) of DSM265 or OZ439
Efficacy of a single 400 mg dose of DSM265 or a 200mg dose of OZ439. The primary efficacy variable is parasite reduction ratio (PRR) of asexual parasites based on qPCR analysis of blood level parasitemia pre-dose and following administration of study drug.
The parasite reduction ratio (PRR) provides an estimate of the efficacy of an antimalarial treatment and is the ratio of the parasite density between admission and 48 h post antimalarial treatment.
Measured: From baseline to 48 hours post antimalarial treatment
Efficacy of OZ439 on P. Vivax
Measured: From baseline to 48 hours post antimalarial treatment
Safety of DSM265 or OZ439 - Number of Adverse Events
Assessement of Adverse Events (AE) (unexpected toxicities, adverse events encountered during or after investigational drug administration)
Measured: From challenge inoculum (day 0) up to day 28 (+/-3 days)
Secondary outcomes (4)
Gametocytemia Clearance With DSM265
Measured: From Drug administration up to day 28 (+/-3 days) following inoculum
P. Vivax Transmission
Measured: From challenge inoculum (day 0) and up to day 28 (+/-3 days)
Parasite Density (Parasite/ml) Assessed by qPCR
Measured: From From drug administration until Standard of Care administration, or up to day 28 (+/-3 days)
Drug Concentration (PK) (ng/ml)
Measured: From From drug administration until Standard of Care administration, or up to day 28 (+/-3 days)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Oct 2015 (estimated)
- Study startOct 2015
- Primary completionMay 2016
- Study completionMay 2016
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for MalariaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1/2
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 16 participants (actual)
Sponsor and investigators
- Lead sponsor
- Medicines for Malaria Venture
- Sponsor type
- University, hospital or other
- Collaborators
- Clinical Network Services (CNS) Pty Ltd, Q-Pharm Pty Limited, Queensland Institute of Medical Research
- Responsible party
- Sponsor
- Investigators
- James McCarthy, Prof, Principal investigator, Q-Pharm Pty Limited
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02573857
- Sponsor's protocol ID
- QP15C11
- Acronym
- DSMOZ-2
- Status last verified
- May 2020
- First submitted
- 6 Oct 2015
- Last updated
- 5 Jun 2020
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
Publications
Dini S, Zaloumis SG, Price DJ, Gobeau N, Kummel A, Cherkaoui M, Moehrle JJ, McCarthy JS, Simpson JA. Seeking an optimal dosing regimen for OZ439/DSM265 combination therapy for treating uncomplicated falciparum malaria. J Antimicrob Chemother. 2021 Aug 12;76(9):2325-2334. doi: 10.1093/jac/dkab181.
PubMed 34179977Collins KA, Abd-Rahman AN, Marquart L, Ballard E, Gobeau N, Griffin P, Chalon S, Mohrle JJ, McCarthy JS. Antimalarial Activity of Artefenomel Against Asexual Parasites and Transmissible Gametocytes During Experimental Blood-Stage Plasmodium vivax Infection. J Infect Dis. 2022 Mar 15;225(6):1062-1069. doi: 10.1093/infdis/jiaa287.
PubMed 32479608Collins KA, Ruckle T, Elliott S, Marquart L, Ballard E, Chalon S, Griffin P, Mohrle JJ, McCarthy JS. DSM265 at 400 Milligrams Clears Asexual Stage Parasites but Not Mature Gametocytes from the Blood of Healthy Subjects Experimentally Infected with Plasmodium falciparum. Antimicrob Agents Chemother. 2019 Mar 27;63(4):e01837-18. doi: 10.1128/AAC.01837-18. Print 2019 Apr.
PubMed 30858218
Study at a glance
From the registry record, last updated by the sponsor on 5 Jun 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase Ib Study to Characterise the Antimalarial and Transmission Blocking Activity of a Single Dose of DSM265 or OZ439 in Healthy Subjects With Induced Blood Stage Plasmodium Falciparum or Plasmodium Vivax Infection
- ClinicalTrials.gov ID
- NCT02573857
- Acronym / sponsor ID
- DSMOZ-2 / QP15C11
- Conditions
- Malaria
- Keywords
- Induced blood stage malaria, Transmission, Gametocytemia
- Phase
- Phase 1/2
- Study type
- Interventional
- Recruitment status
- Terminated
- Enrolment
- 16 participants (actual)
- Lead sponsor
- Medicines for Malaria VentureUniversity, hospital or other
- Collaborators
- Clinical Network Services (CNS) Pty Ltd, Q-Pharm Pty Limited, Queensland Institute of Medical Research
- Study start
- Oct 2015
- Primary completion
- May 2016 (actual)
- Study completion
- May 2016 (actual)
- First posted
- 12 Oct 2015 (estimated)
- Results
- Posted 5 Jun 2020
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Part A
-Cohort 1 DSM265 will be administered as a single dose (400 mg). For cohort 1 only, an additional single dose (400 mg) of DSM265 may be given if gametocytemia develops. Treatment with DSM265 will be given after an overnight fasting period of ≥ 8 hours. If dosing is to occur in the evening, subjects will be required to fast for ≥4 hours prior to receiving treatment. Subjects will be required to fast for a further four hours anytime after dosing with DSM265.
Part B
- Cohort 2 OZ439 will be administered as a single 200 mg dose. If recrudescence is observed, a single 400 mg dose of OZ439 will be given. Treatment with OZ439 will be administered after an overnight fasting period of ≥ 6 hours. If dosing is to occur in the evening, subjects will be required to fast for ≥4 hours prior to receiving treatment. Participants will drink 200 mL of milk prior to drug administration, and then swallow the appropriate volume of OZ439 suspension. Subjects will be required to fast for a further six hours anytime after dosing with OZ439.
- Cohort 3 DSM265 will be administered as a single dose (400 mg) as described for cohort 1. No additional dose will be administered.
Detailed description
This is a single-centre, open label study using induced blood stage malaria (IBSM) infection to assess the effectiveness of the investigational drugs DSM265 or OZ439 in reducing parasitemia. Transmission blocking activity of DSM265 (in P. falciparum infection; cohort 1 only) and infectivity to vector mosquitoes prior to drug treatment (in P. vivax infection; cohort 2 and 3) will also be assessed. This study will be conducted in up to three cohorts (n = 8 per cohort), and will be divided into 2 parts. In Part A (cohort 1) the efficacy of a single administration of 400 mg DSM265 for the clearance of asexual blood stages of P. falciparum will be determined. Activity of a second single dose of 400 mg DSM265 against gametocytes will be assessed in this cohort only if sexual stages are identified by PCR following the initial drug treatment. In Part B, subjects will be infected with P. vivax by IBSM, then treated with a single 200 mg dose OZ439 (cohort 2) or 400 mg dose of DSM265 (cohort 3). For cohort 2, if recrudescence occurs following initial drug treatment with 200 mg OZ439, then affected participants who reach the treatment threshold will receive a single 400 mg dose of OZ439. The PK/PD relationship following drug treatment will be determined in order to further characterize the antimalarial activity of the investigational drug in the IBSM system using P. falciparum (for cohort 1; 400 mg DSM265) or P. vivax (for cohort 2, 200 mg OZ439; cohort 3, 400 mg DSM265).
The treatment effects on gametocytemia (if sexual blood stages are detected by PCR) and transmission blocking activity of DSM265 will be investigated as a secondary objective for cohort 1 (P. falciparum infection). Prior to drug treatment, the infectivity of P. vivax IBSM infection to vector mosquitoes will also be investigated as a secondary objective for Part B, cohorts 2 and 3. The exposures achieved with the doses proposed for DSM265 used in Part A and DSM265 or OZ439 in Part B are associated with a safety profile which is well described from previous studies and significantly below the maximum tolerated exposures reported for either drug.
Study design
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| DSM265 P. falciparum | Experimental | Drug: DSM265Cohort 1: the efficacy of a single administration of 400 mg DSM265 for the clearance of asexual blood stages of P. falciparum will be determined. Activity of a second single dose of 400 mg DSM265 against gametocytes will be assessed in this cohort only if sexual stages are identified by PCR following the initial drug treatment. |
| OZ439 P. vivax | Experimental | Drug: OZ439Cohort 2: subjects will be infected with P. vivax by IBSM, then treated with a single 200 mg dose OZ439. If recrudescence occurs following initial drug treatment with 200 mg OZ439, then affected participants who reach the treatment threshold will receive a single 400 mg dose of OZ439. |
| DSM265 P. vivax | Experimental | Drug: DSM265Cohort 3: subjects will be infected with P. vivax by IBSM, then treated with a single 400 mg dose of DSM265 |
Who may qualify
- Ages
- 18 to 55 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (26 listed)
- Certified as healthy by a comprehensive clinical assessment (detailed medical history and complete physical examination).
- Normal vital signs after 5 minutes resting in supine position:
- Normal standard 12-lead electrocardiogram (ECG) after 5 minutes resting in supine position, QTcF≤450 ms (males and females) with absence of second or third degree atrioventricular block or abnormal T wave morphology.
- Laboratory parameters within the normal range, unless the Investigator considers an abnormality to be clinically irrelevant for healthy participants enrolled in this clinical investigation. More specifically for serum creatinine, hepatic transaminase enzymes (aspartate aminotransferase, alanine aminotransferase), and total bilirubin (unless the Participant has documented Gilbert syndrome) should not exceed the upper laboratory norm and haemoglobin must be equal or higher than the lower limit of the normal range
- As there is the risk of adverse effects of the investigational drugs (DSM265 and OZ439), and standard curative treatment (Riamet and primaquine - cohort 1 only) in pregnancy, it is important that any participants involved in this study do not get pregnant or get their female partners pregnant (refer to Section 6.7).
Key exclusion criteria (52 listed)
- Any history of malaria or participation to a previous malaria challenge study
- Must not have travelled to or lived in a malaria-endemic country during the past 12 months or planned travel to a malaria-endemic country during the course of the study.
- Has evidence of increased cardiovascular disease risk (defined as >10%, 5 year risk) as determined by the Australian Absolute Cardiovascular Disease Risk Calculator (http://www.cvdcheck.org.au/). Risk factors include sex, age, systolic blood pressure (mm/Hg), smoking status, total and HDL cholesterol (mmol/L), and reported diabetes status.
- History of splenectomy.
- Presence or history of drug hypersensitivity, or allergic disease diagnosed and treated by a physician or history of a severe allergic reaction, anaphylaxis or convulsions following any vaccination or infusion.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| DSM265Oral suspension from bulk powder | Drug | DSM265 P. falciparum, DSM265 P. vivax |
| OZ439Also: ArtefenomelOral suspension from powder in a bottle | Drug | OZ439 P. vivax |
Primary outcome
Efficacy (PRR) of DSM265 or OZ439
Time frame: From baseline to 48 hours post antimalarial treatment
Efficacy of a single 400 mg dose of DSM265 or a 200mg dose of OZ439. The primary efficacy variable is parasite reduction ratio (PRR) of asexual parasites based on qPCR analysis of blood level parasitemia pre-dose and following administration of study drug. The parasite reduction ratio (PRR) provides an estimate of the efficacy of an antimalarial treatment and is the ratio of the parasite density between admission and 48 h post antimalarial treatment.
Efficacy of OZ439 on P. Vivax
Time frame: From baseline to 48 hours post antimalarial treatment
Safety of DSM265 or OZ439 - Number of Adverse Events
Time frame: From challenge inoculum (day 0) up to day 28 (+/-3 days)
Assessement of Adverse Events (AE) (unexpected toxicities, adverse events encountered during or after investigational drug administration)
4 secondary outcomes
Gametocytemia Clearance With DSM265
Time frame: From Drug administration up to day 28 (+/-3 days) following inoculum
P. Vivax Transmission
Time frame: From challenge inoculum (day 0) and up to day 28 (+/-3 days)
Parasite Density (Parasite/ml) Assessed by qPCR
Time frame: From From drug administration until Standard of Care administration, or up to day 28 (+/-3 days)
Drug Concentration (PK) (ng/ml)
Time frame: From From drug administration until Standard of Care administration, or up to day 28 (+/-3 days)
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Jun 2020.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 34179977Dini S, Zaloumis SG, Price DJ, Gobeau N, Kummel A, Cherkaoui M, Moehrle JJ, McCarthy JS, Simpson JA. Seeking an optimal dosing regimen for OZ439/DSM265 combination therapy for treating uncomplicated falciparum malaria. J Antimicrob Chemother. 2021 Aug 12;76(9):2325-2334. doi: 10.1093/jac/dkab181.
- Derived from this study: PubMed 32479608Collins KA, Abd-Rahman AN, Marquart L, Ballard E, Gobeau N, Griffin P, Chalon S, Mohrle JJ, McCarthy JS. Antimalarial Activity of Artefenomel Against Asexual Parasites and Transmissible Gametocytes During Experimental Blood-Stage Plasmodium vivax Infection. J Infect Dis. 2022 Mar 15;225(6):1062-1069. doi: 10.1093/infdis/jiaa287.
- Derived from this study: PubMed 30858218Collins KA, Ruckle T, Elliott S, Marquart L, Ballard E, Chalon S, Griffin P, Mohrle JJ, McCarthy JS. DSM265 at 400 Milligrams Clears Asexual Stage Parasites but Not Mature Gametocytes from the Blood of Healthy Subjects Experimentally Infected with Plasmodium falciparum. Antimicrob Agents Chemother. 2019 Mar 27;63(4):e01837-18. doi: 10.1128/AAC.01837-18. Print 2019 Apr.
Related trials for Malaria
Recruiting
The Effects of Iron Treatment on Vaccine Immunogenicity in Kenyan Infants With Iron Deficiency
Iron Deficiencies
Not yet recruiting
Positron Emission Tomography and Organ-Specific Changes in Participants Co-Enrolled in NIH Studies of Plasmodium Vivax Controlled Human Malaria Infection
Healthy Volunteer, Malaria
RecruitingObservational study
Host and Parasite Factors That Influence Susceptibility to Malaria Infection and Disease During Pregnancy and Early Childhood in Ouelessebougou and Bamako, Mali
Malaria
RecruitingPhase 1
Safety, Tolerability and Efficacy of PfSPZ-LARC2 Vaccine Against CHMI in Malaria-Naïve Adults
Malaria Falciparum
Not yet recruiting
Three-arm Cluster Randomised Control Trial Evaluation of Guardian Spatial Emanator as a Complimentary Vector Control Tool in Papua New Guinea
Malaria
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
James McCarthy, Prof principal investigator
Q-Pharm Pty Limited
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1/2 study testing DSM265 and OZ439 in people with Malaria, run by Medicines for Malaria Venture at 1 site in Australia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 26 inclusion and 52 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 5 Jun 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Australia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this combined phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 5 Jun 2020). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Efficacy (PRR) of DSM265 or OZ439 (time frame: From baseline to 48 hours post antimalarial treatment). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02573857, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Jun 2020.